Post-Doctoral Position (1-2 year(s) – January 2025)
Medicinal Chemistry / Biology

UMR 1100 CENTRE d'ETUDE DES PATHOLOGIES RESPIRATOIRES
(CEPR – Tours, France) - https://cepr-inserm.fr/

A 12 months (**renewable up to 24 months**) post-doctoral position is available in the medicinal chemistry group of the CEPR, ideally starting in January 2025. Our laboratory is specialized in respiratory tract infectious, immune, and inflammatory disorders for which it develops both fundamental and translational research programs.

The AEROCURE project, funded by the region Centra-Val de Loire, associates chemists, biologists, inhaled therapy & formulation specialists from both academia & industry, in a multi-disciplinary and dynamic environment, joining hands to develop new therapeutic approaches for the control of acute lung inflammation.

The successful candidate is expected to work in autonomy on the design, synthesis, characterisation, and biological evaluation of a series **heterocyclic small molecules** to optimize them, in line with the target product profile.

Missions:

Synthesis of bioactive compounds, enzymatic evaluation of prepared compounds, analysis of SAR/ADME results, writing of experimental protocols and publications, participation in lab common tasks, communicate in internal and external meetings, supervise students in the lab…

Qualification*:*

Ph.D in organic chemistry / medicinal chemistry, an experience in enzymology would be a strong plus, fluent in written/spoken English

Desired Experience*:*

multi-step synthesis, analytical chemistry (^{1}H and ^{13}C NMR - 1D/2D, HPLC), IT for chemistry (word/excel/powerpoint, Chemdraw/biovia, Pymol, MOE, SciFinder…), a previous post-doc would be a plus.

Environment*:*

≈ 2200e/months net salary (in accordance with previous experiences)
Loire Valley (beautiful chateaux and vineyard) 1h from Paris by train.

Contact & Application:

Dr. Pierre Sierocki (pierre.sierocki@univ-tours.fr), *send Resume + Cover Letters + Brief summary of past research experiences.*

APPLY BEFORE 20th DECEMBER 2024

